文献速递其他结缔组织病

抗CCAR1自身抗体与抗转录中介因子1γ阳性皮肌炎患者较普通人群降低的癌症风险相关

Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.
PubMed 文献 · Arthritis Rheumatol · 2023-05-09

在约翰霍普金斯和斯坦福两个独立队列中,抗CCAR1抗体在抗TIF1γ阳性皮肌炎患者中阳性率80/252(32%),显著高于抗TIF1γ阴性患者的14/186(8%)(P<0.001)。抗TIF1γ阳性皮肌炎患者癌症风险显著高于普通人群,约翰霍普金斯队列SIR 3.49(95%CI 2.39-4.92),斯坦福队列SIR 4.54(95%CI 3.04-6.52)(各P<0.001);而双阳性患者SIR降低至约翰霍普金斯队列1.78(95%CI 0.77-3.51)(P=0.172),斯坦福队列1.61(95%CI 0.44-4.13)(P=0.48)。

要点

  • 抗CCAR1抗体对皮肌炎中的抗TIF1γ阳性亚型具有特异性,健康对照未检出。
  • 抗TIF1γ阳性皮肌炎患者癌症风险显著高于普通人群。
  • 抗CCAR1抗体与抗TIF1γ抗体共存的皮肌炎患者癌症风险降低,SIR与普通人群相近。

核心结论

  • 抗CCAR1自身抗体对皮肌炎中的抗TIF1γ阳性亚型具有特异性,其存在使抗TIF1γ阳性患者的癌症风险降低至与普通人群相当的水平。

研究设计与样本

  • 在约翰霍普金斯和斯坦福两个独立皮肌炎患者队列中,采用酶联免疫吸附试验检测血清抗CCAR1自身抗体频率,并以其他风湿病患者和健康对照作为比较。

主要发现

  • 抗CCAR1抗体在抗TIF1γ阳性皮肌炎患者中阳性80/252(32%),在抗TIF1γ阴性皮肌炎患者中阳性14/186(8%)(P<0.001)。
  • 健康对照32份血清均未检出抗CCAR1抗体;抗HMGCR阳性坏死性肌病44例中1例(2.3%)、包涵体肌炎44例中1例(2.3%)、系统性红斑狼疮46例中3例(6.5%)阳性。
  • 从皮肌炎起病起观察癌症发生,抗TIF1γ阳性皮肌炎患者癌症发生率显著高于普通人群预期,约翰霍普金斯队列SIR 3.49(95%CI 2.39-4.92),斯坦福队列SIR 4.54(95%CI 3.04-6.52)(各P<0.001)。
  • 抗TIF1γ和抗CCAR1双阳性皮肌炎患者癌症SIR降低:约翰霍普金斯队列1.78(95%CI 0.77-3.51)(P=0.172),斯坦福队列1.61(95%CI 0.44-4.13)(P=0.48)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the disease specificity, clinical phenotype, and risk of cancer in dermatomyositis (DM) patients with autoantibodies against cell division cycle and apoptosis regulator protein 1 (anti-CCAR1). METHODS: The frequency of anti-CCAR1 autoantibodies was measured by enzyme-linked immunosorbent assay in the serum of DM patients from 2 independent cohorts (Johns Hopkins and Stanford), with patients with several other rheumatic diseases and healthy controls used as comparators. Clinical features and the risk of cancer incidence relative to that in the general population were determined in anti-CCAR1-positive DM patients. RESULTS: Anti-CCAR1 antibodies were significantly associated with anti-transcriptional intermediary factor 1γ (anti-TIF1γ) antibodies present in the serum of patients with DM: 80 (32%) of 252 anti-TIF1γ-positive DM patients versus 14 (8%) of 186 anti-TIF1γ-negative DM patients were positive for anti-CCAR1 antibodies (P < 0.001). Anti-CCAR1 antibodies were not detected in any of the 32 serum samples from healthy controls, and were present at very low frequencies in the sera of patients with other rheumatic diseases: 1 (2.3%) of 44 patients with anti-hydroxymethylglutaryl-coenzyme A reductase-positive necrotizing myopathy, 1 (2.3%) of 44 patients with inclusion body myositis, and 3 (6.5%) of 46 patients with systemic lupus erythematosus were positive for anti-CCAR1 antibodies. Upon examining data on occurrence of cancer from the onset of DM onward, the observed number of cancers diagnosed in anti-TIF-1γ-positive DM patients was significantly greater than expected in both cohorts, with a standardized incidence ratio (SIR) of 3.49 (95% confidence interval [95% CI] 2.39-4.92) in the Johns Hopkins cohort and a SIR of 4.54 (95% CI 3.04-6.52) in the Stanford cohort (each P < 0.001). DM patients who were both anti-TIF1γ positive and anti-CCAR1 positive had lower SIRs for cancer, with a SIR of 1.78 (95% CI 0.77-3.51) (P = 0.172) in the Johns Hopkins cohort and a SIR of 1.61 (95% CI 0.44-4.13) (P = 0.48) in the Stanford cohort. CONCLUSION: Anti-CCAR1 autoantibodies are specific for anti-TIF1γ-positive DM. Their presence in anti-TIF1γ-positive patients attenuates the risk of cancer to a level comparable to that seen in the general population.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fiorentino D, Mecoli CA, Igusa T, et al. Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis. Arthritis Rheumatol. 2023. PMID: 36762496. doi:10.1002/art.42474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。